

International Symposium on Trends in Radiopharmaceuticals (ISTR-2019)
28 October–1 November 2019, Vienna, Austria

	Monday 28-10-2019	Tuesday 29-10-2019	Wednesday 30-10-2019	Thursday 31-10-2019	Friday 1-11-2019	
09:30–10:30	Registration (8:00 - 9:30)	S.4 Production of radiopharmaceuticals: Theranostic	S.7 Production of radiopharmaceuticals: PET	Clinical advances in nuclear medicine	S.11 Production of alpha emitters and radiopharmaceuticals	
	Opening Session (9:30 - 10:30)	09:00 J. Lewis: Development and application of monoclonal antibody based radiopharmaceuticals	09:00 P. Bisga: Recent advances in the development of ¹⁸ F and ¹¹ C radiopharmaceuticals	09:00 D. Paez: IAEA activities related to nuclear medicine	09:00 A. Morgenstern: Production and quality control of radiopharmaceuticals labelled with Actinium-225 and Bismuth-213	09:00 P. Bisga: Development and performance of a radiopharmacy platform certification, EANM experience
		09:25 C. Decristoforo: Theranostic radiopharmacy	09:25 C. Decristoforo: Recent advances in the development of ⁶⁸ Ga radiopharmaceuticals	09:30 H. Macapinlac: Recent advances in nuclear medicine: Diagnostic and therapy	09:30 C. Cutler: U.S. DOE Tri lab production effort to provide accelerator produced ⁶⁵ Zn	09:20 A. Rey: Education and qualification of radiopharmacists in Latin America
		09:45 V. Gadeltin: Innovative medical radioisotopes for theranostic application, and how they are produced	09:45 I. Aljammaz: Synthesis and in vitro and in vivo evaluation of ¹²⁴ I labelled PSMA peptides: Potential theranostic radiopharmaceuticals for prostate cancer	10:00 D. Le: Production and use of cyclotron-produced radiopharmaceuticals at MD Anderson Cancer Center	10:00 M. Lesinski: Recent results of the joint CNL and TRIUMF project on the production of Ac-225	09:40 N. Bentaleb: Master's degree in radiopharmaceutical sciences: step forward to enhance regional capacities in nuclear medicine in Africa
		10:00 B. Alizadeh: Preparation and preclinical evaluation of ⁶⁴ Cu NOTA-anti MUC1 as a radioimmunoconjugate for diagnosis of MUC1+ breast cancer by PET	10:00 V. Kumar: A radiocopper somatostatin analog (Cu-Sarfatel) for NET theranostics	10:15 W. Chintawan: Comparative study of [¹⁸ F]PSMA-1007 and [⁶⁸ Ga]PSMA-11 for prostate cancer PET imaging in Thailand	10:15 O. Pozzi: Argentinian project for developing production of ²²³ Ac and ²¹³ Bi in cyclotrons for targeted therapy	10:00 E. Janevik-Ivanovska: Developing, testing and installing e-learning system for radiopharmacy as a tool to harmonize education in developing country
		10:15 L. Melendez-Alafort: Development of a new prostate cancer theranostic radiopharmaceutical			10:10 A. Duran: Strengthening capacities for the development of radiotracers labelled with ¹⁸ F, different from fluorodeoxyglucose in the FCDN	10:15 P. Wieland: The World Nuclear University's 7 approaches to enhance professional performance
1030-1100	Morning Coffee Break					
11:00-12:30	S.1 Production of medical radioisotopes: Research Reactor	S.5 Production of radiopharmaceuticals: SPECT	S.8 QA/QC/Pre-clinical	S.12 Emerging radioisotopes for radiopharmacy	WNU OLYMPIAD: FINALS	
	11:00 M. Venkatesh: Production of reactor based radioisotopes: An international scenario	11:00 A. Duatti: Revisiting ^{99m} Tc radiopharmaceuticals with recent advances in chemistry & imaging tools	11:00 S. Rubow: Quality control of hospital based radiopharmaceuticals	11:00 V. Radchenko: Development of production strategies for new emerging research radionuclides using cyclotrons		
	11:25 R. Mikolajczak: Production and supply of medical radioisotopes: A Polish experience	11:25 G. Ferro-Flores: Production of radiolabelled peptides for SPECT-based theranostics	11:20 J. Smith: Development and preclinical evaluation of ¹⁴ C radiolabelled compounds	11:25 M. Ávila Rodríguez: Emerging clinical applications of [⁶⁴ Cu]CuCl ₂ radiopharmaceutical		
	11:45 J.L. Crudo: Laboratory scale production of medium specific activity ¹⁷⁷ Lu (earlier added) through the ¹⁷⁶ Lu (n,γ) ¹⁷⁷ Lu nuclear reaction under standardized conditions	11:45 S. Bouyoucef: Radiopharmacy and growth of nuclear medicine in developing countries	11:40 B. Guérin: Preclinical evaluation of ⁶⁸ Ga-PET tracers using ⁶⁸ Ga produced by cyclotron, a Canadian experience	11:45 P. Martini: Towards large-scale ⁶⁸ Cu cyclotron production		
	12:00 B.R. Ocampo: Synthesis and neutron activation of Lu ₂ O ₃ nanoparticles functionalized with target specific peptides	12:00 C. Balzati: Selective αvβ3 integrin detection using [¹¹¹ In]NPNP43-fogged RGDechi peptides: synthesis and pharmacological studies	12:00 E. Bombardieri: Ethics in animal experiments in nuclear medicine and the application of the directive 2010/63 EU	12:00 I. Cieszykowska: Production of ⁴⁵ Sc from ⁴⁴ Ca comparison of four separation methods		
	12:15 T. Tielens: Towards a robust supply chain for medical radioisotopes	12:15 E. Araújo Perini: The past, present and future trends in radiopharmaceutical production in Brazil	12:15 R. Teodoro: PET for the imaging of cerebral α7 acetylcholine receptors: from tracer development to clinical application	12:15 G. Pupillo: Accelerator-based production of ⁴⁵ Sc: Results of the PASTA project		
12:30-14:00	Lunch Break		Lunch Break (12:30-14:00)			
14:00-15:30	S.2 Production of medical radioisotopes: Accelerators	Poster Session I	S.9 Health regulations: Production of radiopharmaceuticals	Poster Session II	Closing Session / Awards Ceremony	
	14:00 S.M. Qaim: Accelerator based production of non-radionuclides		14:00 S. Kopp: A move towards harmonization of GMP regulations in radiopharmacy			
	14:25 S. Lopi: Production of radiometals using a 24 MeV cyclotron		14:20 C. Decristoforo: The status of radiopharmaceutical regulations in Europe			
	14:45 A. Abrunhosa: Production of radiometals using liquid targets: status and perspectives		14:40 S. Lyashchenko: The status of radiopharmaceutical regulations in the US			
	15:00 J. Haon Park: Radiosotope production and development with 30MeV cyclotron		15:00 Y. Chakrova: GMP certification of radiopharmaceutical production facility in Kazakhstan			
	15:15 V. Radchenko: Production and application of ²²³ Ac/ ²¹³ Bi: TRIUMF experience and perspectives		15:15 S. Nazarenko: Compounding radiopharmaceuticals: any regulatory difference with extemporaneous preparation?			
15:30-16:00	Coffee Break					
16:00-17:30	S.3 Production of medical radioisotopes: Generators	S.6 Production of radiopharmaceuticals: Therapy	S.10 New trends in radiopharmaceuticals: Chemistry	S.13 Radiopharmacy installations		
	16:00 J. Osso Junior: Role of the IAEA on the supply of ⁹⁹ Mo	16:00 M.R.A. Pillai: Production and quality control of bone pain palliation agents using β-emitters	16:00 B. Guérin: Development and evaluation of chelators for specific radiometals	16:00 A. Duatti: How to set up a medium size ^{99m} Tc generator facility: IAEA experience		
	16:15 B. Grimshaw: Safeguards on the production of medical radioisotopes	16:25 J. R. Zeevaert: Comparison of promising new short range therapeutic radiopharmaceuticals using ²²³ Ac, ²¹³ Bi and ¹⁴¹ Tb	16:20 S. Lyashchenko: Novel radiopharmaceuticals for clinical translation	16:25 V. Kumar: Design and successful operation of a SPECT hospital radiopharmacy		
	16:30 C. Cutler: Supply of ⁹⁹ Mo: Focus on US	16:45 V. Chitayil: Freeze-dried kit for quick and efficient preparation of ¹⁸⁸ Re-DED/Apiodal in hospital radiopharmacy	16:40 J. Smith: Translation of new chelators for old pairs: Tc/Re NODAGA, etc	16:45 M.R.A. Pillai: Cyclotron and PET radiopharmacy installation: experience in setting up in a commercial centre		
	16:55 B. Zhujkov: Radionuclide production at high energy accelerators: the new possibilities for radioisotope generators	17:00 C. H. Yeong: Production of Theranostic ¹⁸⁸ Samarium-labelled Polystyrene Microspheres for Hepatic Radioembolization	17:00 K. Katti: Radioactive Gold ¹⁹⁸ Au nanoparticles in nanomedicine	17:00 U. Bhonsle: How to set up a PET radiopharmaceutical facility: IAEA experiences		
	17:15 R. Walczak: Cyclotron production of ⁴⁷ Ca for ⁴⁷ Ca/ ⁴⁷ Sc generator	17:15 A. Chakraborty: Radiolabeling and pre-clinical evolution of Y-90-DOTA-TATE - formulated using Y-90-acetate from high level liquid waste	17:15 P. Brust: New strategies for imaging of brain cancer with radiopharmaceuticals	17:15 K. Washiyama: An effort to diagnostic and therapeutic nuclear medicine at the Fukushima Medical University using two medical cyclotrons		
18:00-20:00	Welcome reception (18:00 - 20:00) MOE		India: Side event			
	Board Room B/M1		MO2			